Revive Therapeutics Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Michael Frank

Chief Executive Officer (CEO)

CA$360.0k

Compensación total

Porcentaje del salario del CEO	100.0%
Permanencia del CEO	4.9yrs
Participación del CEO	0.7%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	4.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Michael Frank en comparación con los beneficios de Revive Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-CA$6m
Mar 31 2024	n/a	n/a	-CA$4m
Dec 31 2023	n/a	n/a	-CA$4m
Sep 30 2023	n/a	n/a	-CA$5m
Jun 30 2023	CA$360k	CA$360k	-CA$6m
Mar 31 2023	n/a	n/a	-CA$8m
Dec 31 2022	n/a	n/a	-CA$12m
Sep 30 2022	n/a	n/a	-CA$15m
Jun 30 2022	CA$360k	CA$360k	-CA$18m
Mar 31 2022	n/a	n/a	-CA$24m
Dec 31 2021	n/a	n/a	-CA$22m
Sep 30 2021	n/a	n/a	-CA$20m
Jun 30 2021	CA$4m	CA$360k	-CA$20m
Mar 31 2021	n/a	n/a	-CA$14m
Dec 31 2020	n/a	n/a	-CA$12m
Sep 30 2020	n/a	n/a	-CA$10m
Jun 30 2020	CA$1m	CA$220k	-CA$5m

Compensación vs. Mercado: La compensación total de Michael($USD256.87K) está por debajo de la media de empresas de tamaño similar en el mercado German ($USD476.59K).

Compensación vs. Ingresos: La compensación de Michael ha sido consistente con los resultados de la empresa en el último año.

CEO

Michael Frank (63 yo)

4.9yrs

Permanencia

CA$360,000

Compensación

Mr. Michael Frank is Chairman and Chief Executive Officer of Revive Therapeutics Ltd. since December 18, 2019 and its Director. He served as Chairman and CEO at The Good Shroom Co Inc. till April 15, 2021....

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Michael Frank	Chairman & CEO	4.9yrs	CA$360.00k	0.75% € 21.2k
William Jackson	Independent Director	10.8yrs	sin datos	0.16% € 4.4k
Andrew Lindzon	Independent Director	4.9yrs	sin datos	0.13% € 3.6k
Christian Scovenna	Independent Director	4.9yrs	sin datos	0.48% € 13.5k
Joshua Herman	Independent Director	4.9yrs	sin datos	0.15% € 4.2k

4.9yrs

Permanencia media

62.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 31R se considera experimentada (4.9 años de antigüedad promedio).

Revive Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Revive Therapeutics Ltd., Annual General Meeting, Dec 19, 2023

High number of new and inexperienced directors

Revive Therapeutics Ltd., Annual General Meeting, Aug 03, 2022

High number of new and inexperienced directors

Revive Therapeutics Ltd., Annual General Meeting, Apr 05, 2021

Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study

Recent updates

Revive Therapeutics Ltd. Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

Revive Therapeutics Ltd. Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

Revive Therapeutics Ltd. Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

Revive Therapeutics Ltd. Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long Covid

Revive Therapeutics Ltd. Provides Update from FDA Meeting for Long Covid Diagnostic Product

New major risk - Financial position

Revive Therapeutics Ltd. Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product

Revive Therapeutics Ltd. Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID

Revive Therapeutics Ltd. announced that it has received CAD 2.10061 million in funding

Revive Therapeutics Explores the Use of Bucillamine for Long COVID

New minor risk - Shareholder dilution

Revive Therapeutics Ltd. announced that it expects to receive CAD 3 million in funding

Revive Therapeutics Ltd. Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada

Revive Therapeutics Ltd. Successfully Completes Development of A Novel Lyophilized Formulation of Bucillamine

Revive Therapeutics Ltd. Provides Update of Novel Bucillamine Formulation Development

Revive Therapeutics Ltd. Provides Update of Novel Bucillamine Formulation Development

Revive Therapeutics Ltd., Annual General Meeting, Dec 19, 2023

New major risk - Market cap size

Revive Therapeutics Ltd. Announces Initiation of Novel Bucillamine Formulation Development

New major risk - Market cap size

Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Ltd. Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Ltd. Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of Covid-19

Revive Therapeutics Ltd. To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Ltd. Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of Covid-19

Revive Therapeutics Ltd. announced that it expects to receive CAD 5 million in funding from EMD Financial Inc.

Revive Therapeutics Ltd. announced that it expects to receive CAD 5 million in funding from EMD Financial Inc.

Revive Therapeutics Ltd. Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

High number of new and inexperienced directors

Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in Covid-19

Revive Therapeutics Ltd. Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program

Revive Therapeutics Ltd. Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in Covid-19

Revive Therapeutics Ltd. Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd., Annual General Meeting, Aug 03, 2022

Revive Therapeutics Ltd. Provides Update on U.S. Food & Drug Administration Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. Advances Inflammatory Liver Disorders Programs for Autoimmune Hepatitis and Liver Transplantation

Revive Therapeutics Ltd. Provides Update on Phase 3 Clinical Trial for Bucillamine in Covid-19

Revive Therapeutics Ltd. Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

High number of new and inexperienced directors

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Announces Publication of Research Data with Bucillamine in Covid-19

Revive Therapeutics Ltd. Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. Provides Update on Phase 3 Clinical Trial for Bucillamine in Covid-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

Revive Therapeutics Ltd. to Provide an Update on its Psychedelics Development and Clinical Programs with a Focus on Psilocybin

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application

Revive Therapeutics Ltd. Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request

Revive Therapeutics Ltd. Provides Update on Cannabinoid Pharmaceuticals Program

Revive Therapeutics Ltd., Annual General Meeting, Apr 05, 2021

Revive Therapeutics Announces Research Collaboration with North Carolina State University

Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access

Revive Therapeutics Ltd. Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics

Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin

Revive Therapeutics Ltd. Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. Announces Clinical Study of Psilocybin in the Treatment of Methamphetamine Use Disorder

Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19

Análisis de compensación del CEO